Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von fchar99 

Moleculin Biotech Inc diskutieren

Moleculin Biotech Inc

WKN: A2QQM0 / Symbol: MBRX / Name: Moleculin Biotech / Aktie / Pharmazeutika / Micro Cap /

0,41 €
1,53 %

8 0
8
0
Einschätzung Buy
Rendite (%) -
Kursziel 3,70
Veränderung
Endet am 25.03.26

Moleculin Biotech, Inc. (NASDAQ: MBRX) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat

Maxim Group 
0
Melden Teilen
25.03.25
Einschätzung Buy
Rendite (%) -
Kursziel 3,50
Veränderung
Endet am 09.06.26

Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat

HC Wainwright 
0
Melden Teilen
09.06.25
Einschätzung Buy
Rendite (%) -
Kursziel 3,48
Veränderung
Endet am 18.06.26

Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat

HC Wainwright 
0
Melden Teilen
18.06.25
Einschätzung Buy
Rendite (%) -
Kursziel 3,44
Veränderung
Endet am 27.08.26

Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat

HC Wainwright 
0
Melden Teilen
27.08.25
Einschätzung Buy
Rendite (%) -
Kursziel 3,42
Veränderung
Endet am 10.09.26

Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat

HC Wainwright 
0
Melden Teilen
10.09.25

Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Ratings data for MBRX provided by MarketBeat

Roth Capital 
0
Melden Teilen
15.12.25 Buy -
Einschätzung Buy
Rendite (%) -
Kursziel 18,98
Veränderung
Endet am 24.03.27

Moleculin Biotech (MBRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat

HC Wainwright 
0
Melden Teilen
15:30
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

SVB_Leerink_LLC in Insmed Inc. diskutieren
Insmed (INSM) had its price target raised by Leerink Part...
17:00
HC_Wainwright in Moleculin Biotech Inc diskutieren
Moleculin Biotech (MBRX) had its "buy" rating reaffirmed ...
15:30
Royal_Bank_of_Canada in Transalta Corp. diskutieren
TransAlta (NYSE:TAC) (TSE:TA) had its "outperform" rating...
15:30
HC_Wainwright in Sutro Biopharma Inc diskutieren
Sutro Biopharma (STRO) was upgraded by HC Wainwright from...
15:00
BTIG_Research in Avalo Therapeutics Inc. diskutieren
Avalo Therapeutics (AVTX) had its "buy" rating reaffirmed...
15:00
National_Bank_Financ in Transalta Corp. diskutieren
TransAlta (NYSE:TAC) (TSE:TA) was upgraded by National Ba...
15:00
Wells_Fargo___Compan in Sutro Biopharma Inc diskutieren
Sutro Biopharma (STRO) was upgraded by Wells Fargo & ...
15:00
Bank_of_America_Co_ in Insmed Inc. diskutieren
Insmed (INSM) had its price target raised by Bank of Amer...
15:00
Mehr anzeigen